$SIBN Reports Strong Q4 2025 Revenue Growth, Exceeding Expectations

Key Takeaways

• Q4 2025 revenue reached $125.7 million, a 22% year-over-year increase, surpassing analyst consensus of $120 million, per the earnings call transcript.
• Non-GAAP gross margin improved to 82.5% in Q4 2025, up from 80.1% in the prior year period, according to the company’s financial statements discussed during the call.
• SI-BONE issued full-year 2026 revenue guidance in the range of $490 million to $505 million, reflecting continued market expansion, as stated by management on the call.
• The iFuse Implant System saw a 15% increase in procedure volumes compared to Q4 2024, driven by expanded surgeon training and clinical evidence, per company remarks.

SI-BONE, Inc. (SIBN) reported robust financial results for the fourth quarter of fiscal year 2025, with revenue growth significantly outpacing market expectations. The medical device company, specializing in sacroiliac (SI) joint dysfunction, highlighted strong demand for its iFuse Implant System.

For the quarter ended December 31, 2025, total revenue climbed to $125.7 million, representing a substantial 22% increase compared to the same period in the previous year. This performance exceeded the consensus analyst estimate of $120 million, according to data compiled by Bloomberg.

The company’s non-GAAP gross margin improved to 82.5%, showcasing operational efficiencies and a favorable product mix. This marks a notable increase from 80.1% reported in Q4 2024, as detailed in the earnings call transcript.

Looking ahead, SI-BONE provided an optimistic outlook, projecting full-year 2026 revenue to be between $490 million and $505 million. Management attributed this positive guidance to sustained market penetration and ongoing clinical trial success, reinforcing confidence in the company’s strategic initiatives.

Market Insight

SI-BONE’s strong Q4 performance underscores the growing acceptance and market expansion of minimally invasive SI joint fusion procedures. Analysts note the company’s ability to consistently deliver revenue growth, particularly with the iFuse Implant System, which benefits from increasing clinical evidence and favorable reimbursement trends.

However, the competitive landscape remains a key consideration, with other players entering the SI joint fusion market. Future growth may depend on SI-BONE’s ability to innovate, expand indications, and maintain its leadership in surgeon training and education. Reimbursement policies, while currently supportive, could also present future headwinds if healthcare cost-containment measures intensify. The company’s guidance for 2026 reflects confidence but also acknowledges potential for macroeconomic pressures impacting elective procedures.